Related Experiment Videos
Improved patency of the aortocoronary bypass by antithrombotic drugs
Insights
Antiplatelet drugs, including acetylsalicylic acid and dipyridamole, significantly improved aortocoronary bypass graft patency in patients with low intraoperative blood flow rates. This treatment enhanced both short-term and long-term graft survival.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Medical Technology
Background:
- Aortocoronary bypass surgery (ACBs) is a critical intervention for coronary artery disease.
- Graft patency is a key determinant of long-term surgical success.
- Low intraoperative blood flow rates (<40 ml/min) are associated with increased graft occlusion.
Purpose of the Study:
- To evaluate the efficacy of antiplatelet therapy in improving the patency of low-flow aortocoronary bypass grafts.
- To assess the impact of acetylsalicylic acid and dipyridamole on short-term and long-term graft survival.
Main Methods:
- A prospective study involving 442 patients undergoing 1,017 bypasses.
- Patients with low-flow ACBs were randomized into a treated group (acetylsalicylic acid + dipyridamole) and a control group (no medication).
- Graft patency was assessed by coronary arteriography at one month and one year postoperatively.
Main Results:
- The treated group showed significantly higher patency rates: 34/41 (82.9%) at one month and 24/37 (64.9%) at one year.
- The control group had lower patency rates: 17/37 (45.9%) at one month and 8/38 (21.1%) at one year (p < .001 for both comparisons).
- Low-flow grafts were identified as a significant risk factor for occlusion.
Conclusions:
- Combined antiplatelet therapy with acetylsalicylic acid and dipyridamole significantly enhances both short-term and long-term patency of low-flow aortocoronary bypass grafts.
- This therapeutic strategy offers a beneficial approach to improve outcomes in selected bypass graft patients.
- Early identification and management of low-flow grafts are crucial for preventing occlusion.
Abstract:
A total of 1,017 bypasses were performed in 442 patients operated on in our department between January 1, 1981, and May 30, 1984. The overall early postoperative graft patency rate in our hospital was 91.5%. About 10% of the grafts had a flow rate of 40 ml/min or less, measured intraoperatively, and most occluded grafts were in this group. This article presents our experience with low-flow bypasses whose patency rates we attempted to improve. Patients with aortocoronary bypasses (ACBs) and with intraoperative blood flow rates of 40 ml/min or less were divided into two groups. The treated group was given, from day 0 onward, a 500-mg dose of acetylsalicylic acid twice a day and a 75-mg dose of dipyridamole three times a day. The control group was given no medication. Control coronary arteriography was performed at one month and then at one year after the operation. One month postoperatively, 34 out of 41 ACBs in the treated group were patent; in the control group, only 17 out of 37 were patent (p less than .001). One year after the operation, 24 out of 37 ACBs in the treated group were patent, whereas in the control group only 8 out of 38 ACBs were patent (p less than .001). We conclude that antiplatelet drugs have a beneficial effect on the short-term and long-term patency of ACBs.